Copy to clipboard 
ORTHOWORLD estimates Integra LifeSciences’ 2Q17 orthopaedic revenue at US $37.3MM, +34.1% from 2Q16, and 1H17 revenue of $68.5MM, +27.1% vs. 1H16.
| 2Q17 | 2Q16 | $ Change | % Change | |
| Joint Recon Extremities | $8.3 | $5.7 | $2.6 | 45.9% |
| Trauma | $29.0 | $22.1 | $6.9 | 31.1% |
| Total | $37.3 | $27.8 | $9.5 | 34.1% |
| 1H17 | 1H16 | $ Change | % Change | |
| Joint Recon Extremities | $14.4 | $10.8 | $3.6 | 33.1% |
| Trauma | $54.1 | $43.1 | $11.0 | 25.6% |
| Total | $68.5 | $53.9 | $14.6 | 27.1% |
Performance highlights:
- Joint Recon Extremities growth driven by Cadence and Salto ankles, Titan Shoulder
- Total ankles generated ~50% organic growth; Titan led double-digit increase in upper extremity recon
- Titan growth supported by expansion of distributor network, adding new surgeons from Integrated Delivery Network contract signed earlier in 2017—including conversions from competition
- In end of 2Q/into 3Q, added non-commissioned associate sales reps to run cases, freeing key reps to target new business
- Still working through updates to broader extremities portfolio (non-joint-recon)
- Acquired TGX Medical, developer of software to track surgical instruments from OR to sterilization to storage, ensuring proper cleaning, assembly and maintenance; while orthopaedic application was not specifically mentioned, it’s reasonable to expect the platform could be used to support ortho procedures
Sources: Integra LifeSciences Corporation; SEC.gov; ORTHOWORLD estimates
ORTHOWORLD estimates Integra LifeSciences’ 2Q17 orthopaedic revenue at US $37.3MM, +34.1% from 2Q16, and 1H17 revenue of $68.5MM, +27.1% vs. 1H16.
Q17
Q16
$ Change
% Change
Joint Recon Extremities
$8.3 ...
ORTHOWORLD estimates Integra LifeSciences’ 2Q17 orthopaedic revenue at US $37.3MM, +34.1% from 2Q16, and 1H17 revenue of $68.5MM, +27.1% vs. 1H16.
| 2Q17 | 2Q16 | $ Change | % Change | |
| Joint Recon Extremities | $8.3 | $5.7 | $2.6 | 45.9% |
| Trauma | $29.0 | $22.1 | $6.9 | 31.1% |
| Total | $37.3 | $27.8 | $9.5 | 34.1% |
| 1H17 | 1H16 | $ Change | % Change | |
| Joint Recon Extremities | $14.4 | $10.8 | $3.6 | 33.1% |
| Trauma | $54.1 | $43.1 | $11.0 | 25.6% |
| Total | $68.5 | $53.9 | $14.6 | 27.1% |
Performance highlights:
- Joint Recon Extremities growth driven by Cadence and Salto ankles, Titan Shoulder
- Total ankles generated ~50% organic growth; Titan led double-digit increase in upper extremity recon
- Titan growth supported by expansion of distributor network, adding new surgeons from Integrated Delivery Network contract signed earlier in 2017—including conversions from competition
- In end of 2Q/into 3Q, added non-commissioned associate sales reps to run cases, freeing key reps to target new business
- Still working through updates to broader extremities portfolio (non-joint-recon)
- Acquired TGX Medical, developer of software to track surgical instruments from OR to sterilization to storage, ensuring proper cleaning, assembly and maintenance; while orthopaedic application was not specifically mentioned, it’s reasonable to expect the platform could be used to support ortho procedures
Sources: Integra LifeSciences Corporation; SEC.gov; ORTHOWORLD estimates
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
